What's Happening?
Ollin Biosciences, a clinical-stage biopharmaceutical company, announced the upcoming presentation of 20-week data from its Phase 1b JADE clinical study. This study compares OLN324, a VEGF/Ang2 bispecific antibody, to faricimab (Vabysmo®) in patients
with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). The data will be presented at the Clinical Trials at the Summit 2026 in Las Vegas. OLN324 has shown faster and greater anatomic outcomes and vision gains compared to faricimab. The company plans to initiate Phase 3 trials in the second half of 2026.
Why It's Important?
The presentation of OLN324's data is significant as it highlights advancements in treatments for vision-threatening diseases like DME and wAMD. These conditions affect millions and can lead to severe vision loss. The promising results of OLN324 could offer a more effective treatment option, potentially improving patient outcomes. This development also underscores Ollin Biosciences' role in innovating within the ophthalmology sector, which could influence future research and treatment protocols.
What's Next?
Ollin Biosciences plans to advance OLN324 into Phase 3 clinical trials later in 2026. These trials will further evaluate the efficacy and safety of OLN324 in a larger patient population. The outcomes of these trials could lead to regulatory approval and commercialization, providing a new treatment option for patients with DME and wAMD. The company’s continued collaboration with Innovent Biologics will be crucial in these next steps.
